Table 1.
Characterization | PNA-immobilized fluorescent nanospheres | Lectin-free fluorescent nanospheres with PNVA and PMAA chains | Lectin-free fluorescent nanospheres with PNVA chains |
---|---|---|---|
Molecular weight of PNVA (Mw/Mn) | → | 9500/4000 | 9500/4000 |
Molecular weight of PMAA (Mw/Mn) | → | 10000/5600 | -h |
Particle size (nm)a | -g | 302 ± 80 | 384 ± 90 |
Zeta potential (mV)b | -g | -21.8 | -2.8 |
Encapsulated coumarin 6 (μg/mg)c | → | 0.8 | 1.0 |
Immobilized PNA (μg/mg)d | 6.6 | -h | -h |
Minimum conc. of PNA for agglutination of neuraminidase-treated erythrocytes (μg/mL)e | 0.032 | -h | -h |
Minimum conc. of PNA for agglutination of neuraminidase-untreated erythrocytes (μg/mL)f | >33.0 | -h | -h |
Weight-average diameter (mean ± s.d.)
Measured in neutral PBS (without CaCl2 and MgCl2) at 25°C
Encapsulated amount (μg) of coumarin 6 per milligram of the imaging agent and its precursor.
Immobilized amount (μg) of PNA per milligram of the imaging agent.
Minimum concentration of PNA immobilized on the nanospheres surface that induced neuraminidase-treated (Gal-β(1-3)GalNAc-expressed) erythrocyte agglutination.
Minimum concentration of PNA immobilized on the nanospheres surface that induced neuraminidase-untreated erythrocyte agglutination.
Not tested
Not required